A Practical Roadmap for Diagnosing and Treating DED, With Drs. Lisa Nijm and Vance Thompson ..read more

In this educational activity, faculty discuss recent developments in ocular surface disease presented at the Fall 2022 academic conferences ..read more

In this podcast, expert clinicians will discuss current and future approaches for the management of patients with uveitis ..read more

In this podcast, expert clinicians will discuss the utilization of surgery in the management of patients with retinal diseases ..read more

In this podcast, expert clinicians will discuss the utilization of imaging in patients with retinal diseases ..read more

In this podcast, expert clinicians will discuss current and future approaches for the management of patients with neovascular age-related macular degeneration, dry age-related macular degeneration, and geographic atrophy ..read more

In this podcast, expert clinicians will discuss current and future approaches for the management of patients with diabetic eye disease ..read more

The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potenti ..read more

The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potenti ..read more

The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potenti ..read more